The Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small-Cap Research, will take place on June 24 and 25, 2026, featuring 23 public companies from the life sciences sector. The event is powered by B2i Digital, Inc., which serves as the Official Marketing Partner, leveraging its distribution network to reach over 1.7 million market participants.
The two-day forum spans clinical-stage biotechnology, rare-disease and oncology therapeutics, molecular diagnostics, medical devices, veterinary medicine, nutrition science, and AI-powered digital health. Each presenting company will have 30 minutes for a live presentation and real-time Q&A, with one-on-one meeting requests available through the AxleAccess platform.
Day one on June 24 begins at 9:30 AM ET with Protalix BioTherapeutics, Inc., followed by MetaVia Inc., CytoSorbents Corporation, PetVivo Holdings Inc., Jaguar Health, Inc., Reviva Pharmaceuticals Holdings, Inc., and 4DMedical Ltd. Day two on June 25 starts at 9:30 AM ET with Prostatype Genomics AB, then Abingdon Health plc, Innovotech, Inc., Lakewood-Amedex Biotherapeutics Inc., Nasus Pharma Ltd., Kelyniam Global, Inc., IMUNON, Inc., Promino Nutritional Sciences Inc., Envoy Medical Inc., Coiled Therapeutics plc, Aspire Biopharma Holdings Inc., Rocket Doctor AI Inc., Phio Pharmaceuticals Corp., aTyr Pharma, Inc., and NuFarm Ltd.
Zacks Small-Cap Research, a preferred provider in the OTC Markets Group's Research Marketplace, co-hosts the forum, bringing independent company-sponsored research to the event. According to David Shapiro, CEO of B2i Digital, “Life sciences investors want efficient, direct access to management teams developing the therapies and technologies that matter, and pairing that access with independent research from Zacks makes the forum more valuable on both sides.”
Replays of the presentations will be available on B2i Digital and OTC Markets YouTube channels. Registration and company profiles can be accessed via the Virtual Investor Conferences website. The event underscores the growing trend of virtual forums that provide direct engagement between investors and life sciences companies, reducing barriers to information and fostering informed investment decisions.
